Deltec Asset Management LLC Invests $107,000 in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Deltec Asset Management LLC purchased a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 200,000 shares of the biopharmaceutical company’s stock, valued at approximately $107,000. Deltec Asset Management LLC owned 0.36% of Marinus Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its stake in Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 126,752 shares during the period. Franklin Resources Inc. lifted its position in shares of Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after buying an additional 1,219,871 shares during the period. World Investment Advisors LLC acquired a new stake in Marinus Pharmaceuticals in the 3rd quarter valued at $104,000. Jacobs Levy Equity Management Inc. grew its position in Marinus Pharmaceuticals by 39.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 117,255 shares during the period. Finally, Suvretta Capital Management LLC raised its stake in Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares in the last quarter. 98.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

MRNS has been the topic of several recent analyst reports. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. HC Wainwright restated a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Royal Bank of Canada dropped their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a report on Friday, October 25th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Marinus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Price Performance

NASDAQ MRNS opened at $0.55 on Wednesday. Marinus Pharmaceuticals, Inc. has a 52-week low of $0.22 and a 52-week high of $10.50. The business has a 50 day simple moving average of $0.42 and a 200 day simple moving average of $0.93.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.